Skip to content
Screener

Opus Genetics IRD Q4 2025 Annual earnings

Reported May 21, 2026 · Before market open

Revenue$3.9MBeat by $721.0K
EPS-$0.19Miss by $0.03
Revenue estimate$3.1M
EPS estimate-$0.16

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$1.5M
EPS estimate-$0.14

Financials

Q4 2025

Income statement

See full
Revenue$3.9M-10.2%
Operating income-$11.5M+69.9%
Net income-$16.5M+53.0%
EPS (diluted)-$0.21+83.5%

Balance sheet

See full
Cash & equivalents$45.1M+48.7%
Total debt$1.1M—
Total equity$15.3M+128%
Total assets$50.2M+36.3%

Cash flow

See full
Operating cash flow-$9.8M-32.2%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$138.62M+269%
Enterprise value$94.66M—
P/S9.8×+6.3×

Profitability

See full
Operating margin-271.9%-92.8pp
Net margin-349.3%-87.2pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×—
Current ratio6.4×+3.2×

FAQ

When did Opus Genetics report Q4 2025 earnings?
Opus Genetics (IRD) reported Q4 2025 earnings on May 21, 2026 before market open.
What were Opus Genetics's Q4 2025 revenue and EPS?
Opus Genetics reported revenue of $3.9M and eps of $-0.19 for Q4 2025.
Did Opus Genetics beat estimates in Q4 2025?
Revenue beat the consensus estimate of $3.1M by $721.0K. EPS missed the consensus estimate of $-0.16 by $0.03.
How did Opus Genetics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 10.2% from $4.3M a year earlier and eps grew 85.0% from $-1.27.
Where can I find Opus Genetics's Q4 2025 SEC filings?
You can read the 10-K periodic report (0001140361-26-009247) directly on SEC EDGAR. The filing index links above go to sec.gov.